Multicompartimental nanoparticles for Co-encapsulation and multimodal drug delivery to tumor cells and neovasculature

Pharmaceutical Research

Volumn 31, Issue 5, 2014, Pages 1106-1119

  Mendes, Lívia Palmerston ^a   Gaeti, Marilisa Pedroso Nogueira ^a   De Ávila, Paulo Henrique Marcelino ^a   De Sousa Vieira, Marcelo ^a   Dos Santos Rodrigues, Bruna ^a   De Ávila Marcelino, Renato Ivan ^a   Dos Santos, Lílian Cristina Rosa ^a   Valadares, Marize Campos ^a   Lima, Eliana Martins ^a  

^a FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

Author keywords

antiangiogenesis; antitumoral; co encapsulation; multicompartimental nanoparticles; temporal drug release

Indexed keywords

COATED NANOPARTICLE; DRUG CARRIER; GENISTEIN; NANOPARTICLE; PACLITAXEL; POLYGLACTIN; UNCLASSIFIED DRUG; UNCOATED NANOPARTICLE; VASCULOTROPIN; ANTINEOPLASTIC AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASCITES FLUID; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG SOLUBILITY; EHRLICH ASCITES TUMOR; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; LIGHT SCATTERING; MALE; MOUSE; NANOENCAPSULATION; NONHUMAN; PHOSPHOLIPID BILAYER; PRIORITY JOURNAL; SUSTAINED DRUG RELEASE; TUMOR CELL; ANIMAL; BLOOD VESSEL; METABOLISM; NEOPLASMS, EXPERIMENTAL; PATHOLOGY; TRANSMISSION ELECTRON MICROSCOPY;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD VESSELS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG DELIVERY SYSTEMS; GENISTEIN; MALE; MICE; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; NEOPLASMS, EXPERIMENTAL; PACLITAXEL;

EID: 84902287623     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-013-1234-x     Document Type: Article

References (57)

1. Uramoto H, Nakanishi R, Nagashima A, Uchiyama A, Inoue M, Osaki T, et al. A randomized phase II trial of adjuvant chemotherapy with bi-weekly carboplatin plus paclitaxel versus carboplatin plus gemcitabine in patients with completely resected non-small cell lung cancer. Anticancer Res. 2010;30(11):4695-9.
2. Pishvaian MJ, Slack R, Koh EY, Beumer JH, Hartley ML, Cotarla I, et al. A phase I clinical trial of the combination of imatinib and paclitaxel in patients with advanced or metastatic solid tumors refractory to standard therapy. Cancer Chemother Pharmacol. 2012;70(6):843-53.
3. Feng S-S, Zhao L, Zhang Z, Bhakta G, Yin Win K, Dong Y, et al. Chemotherapeutic engineering: vitamin E TPGS-emulsified nanoparticles of biodegradable polymers realized sustainable paclitaxel chemotherapy for 168 h in vivo. Chem Eng Sci. 2007;62(23):6641-8.
4. Burris 3rd HA, Dowlati A, Moss RA, Infante JR, Jones SF, Spigel DR, et al. Phase I study of pazopanib in combination with paclitaxel and carboplatin given every 21 days in patients with advanced solid tumors. Mol Cancer Ther. 2012;11(8):1820-8.
5. Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer. 2001;37(13):1590-8.
6. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005;23(31):7794-803.
7. Alberts DS, Blessing JA, Landrum LM, Warshal DP, Martin LP, Rose SL, et al. Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: a gynecologic oncology group study. Gynecol Oncol. 2012;127(3):451-5.
8. Frese KK, Neesse A, Cook N, Bapiro TE, Lolkema MP, Jodrell DI, et al. nab-paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. Cancer Discov. 2012;2(3):260-9.
9. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357(26):2666-76.
10. Cella D, Wang M, Wagner L, Miller K. Survival-adjusted health-related quality of life (HRQL) among patients with metastatic breast cancer receiving paclitaxel plus bevacizumab versus paclitaxel alone: results from Eastern Cooperative Oncology Group Study 2100 (E2100). Breast Cancer Res Treat. 2011;130(3):855-61.
11. Wang Z, Chui WK, Ho PC. Nanoparticulate delivery system targeted to tumor neovasculature for combined anticancer and antiangiogenesis therapy. Pharm Res. 2011;28(3):585-96.
12. Ahmed F, Pakunlu RI, Brannan A, Bates F, Minko T, Discher DE. Biodegradable polymersomes loaded with both paclitaxel and doxorubicin permeate and shrink tumors, inducing apoptosis in proportion to accumulated drug. J Control Release. 2006;116(2):150-8.
13. Guo C, Liu S, Dai Z, Jiang C, Li W. Polydiacetylene vesicles as a novel drug sustained-release system. Colloids Surf B: Biointerfaces. 2010;76(1):362-5.
14. Wang C, Wang Y, Fan M, Luo F, Qian Z. Characterization, pharmacokinetics and disposition of novel nanoscale preparations of paclitaxel. Int J Pharm. 2011;414(1-2):251-9.
15. Wu J, Lu Y, Lee A, Pan X, Yang X, Zhao X, et al. Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil. J Pharm Pharm Sci. 2007;10(3):350-7.
16. Wang H, Zhao Y, Wu Y, Hu YL, Nan K, Nie G, et al. Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles. Biomaterials. 2011;32(32):8281-90.
17. Cosco D, Paolino D, Maiuolo J, Russo D, Fresta M. Liposomes as multicompartmental carriers for multidrug delivery in anticancer chemotherapy. Drug Deliv Transl Res. 2011;1:66-75.
18. Bamias A, Pignata S, Pujade-Lauraine E. Angiogenesis: a promising therapeutic target for ovarian cancer. Crit Rev Oncol Hematol. 2012.
19. El-Azab M, Hishe H, Moustafa Y, el El-Awady S. Anti-angiogenic effect of resveratrol or curcumin in Ehrlich ascites carcinoma-bearing mice. Eur J Pharmacol. 2011;652(1-3):7-14.
20. Sheela ML, Ramakrishna MK, Salimath BP. Angiogenic and proliferative effects of the cytokine VEGF in Ehrlich ascites tumor cells is inhibited by Glycyrrhiza glabra. Int Immunopharmacol. 2006;6(3):494-8.
21. Wang Z, Ho PC. Self-assembled core-shell vascular-targeted nanocapsules for temporal antivasculature and anticancer activities. Small. 2010;6(22):2576-83.
22. Su SJ, Yeh TM, Chuang WJ, Ho CL, Chang KL, Cheng HL, et al. The novel targets for anti-angiogenesis of genistein on human cancer cells. Biochem Pharmacol. 2005;69(2):307-18.
23. Pavese JM, Farmer RL, Bergan RC. Inhibition of cancer cell invasion and metastasis by genistein. Cancer Metastasis Rev. 2010;29(3):465-82.
24. Yu X, Zhu J, Mi M, Chen W, Pan Q, Wei M. Anti-angiogenic genistein inhibits VEGF-induced endothelial cell activation by decreasing PTK activity and MAPK activation. Med Oncol. 2012;29(1):349-57.
25. Blagosklonny MV. Antiangiogenic therapy and tumor progression. Cancer Cell. 2004;5(1):13-7.
26. Hwang JT, Ha J, Park OJ. Combination of 5-fluorouracil and genistein induces apoptosis synergistically in chemo-resistant cancer cells through the modulation of AMPK and COX-2 signaling pathways. Biochem Biophys Res Commun. 2005;332(2):433-40.
27. Li Y, Kucuk O, Hussain M, Abrams J, Cher ML, Sarkar FH. Antitumor and antimetastatic activities of docetaxel are enhanced by genistein through regulation of osteoprotegerin/receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/MMP-9 signaling in prostate cancer. Cancer Res. 2006;66(9):4816-25.
28. Zhang B, Shi ZL, Liu B, Yan XB, Feng J, Tao HM. Enhanced anticancer effect of gemcitabine by genistein in osteosarcoma: the role of Akt and nuclear factor-kappaB. Anticancer Drugs. 2010;21(3):288-96.
29. Filipe V, Hawe A, Jiskoot W. Critical evaluation of Nanoparticle Tracking Analysis (NTA) by NanoSight for the measurement of nanoparticles and protein aggregates. Pharm Res. 2010;27(5):796-810.
30. Mengual O, Meunier G, Cayre I, Puech K, Snabre P. TURBISCAN MA 2000: multiple light scattering measurement for concentrated emulsion and suspension instability analysis. Talanta. 1999;50(2):445-56.
31. Nogueira IA, Leao AB, Vieira Mde S, Benfica PL, da Cunha LC, Valadares MC. Antitumoral and antiangiogenic activity of Synadenium umbellatum Pax. J Ethnopharmacol. 2008;120(3):474-8.
32. Teicher BA, Sotomayor EA, Huang ZD. Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res. 1992;52(23):6702-4.
33. Folkins C, Man S, Xu P, Shaked Y, Hicklin DJ, Kerbel RS. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res. 2007;67(8):3560-4.
34. Casneuf VF, Demetter P, Boterberg T, Delrue L, Peeters M, Van Damme N. Antiangiogenic versus cytotoxic therapeutic approaches in a mouse model of pancreatic cancer: an experimental study with a multitarget tyrosine kinase inhibitor (sunitinib), gemcitabine and radiotherapy. Oncol Rep. 2009;22(1):105-13.
35. Al-Ghananeem AM, Malkawi AH, Muammer YM, Balko JM, Black EP, Mourad W, et al. Intratumoral delivery of paclitaxel in solid tumor from biodegradable hyaluronan nanoparticle formulations. AAPS PharmSciTech. 2009;10(2):410-7.
36. Mo Y, Lim LY. Paclitaxel-loaded PLGA nanoparticles: potentiation of anticancer activity by surface conjugation with wheat germ agglutinin. J Control Release. 2005;108(2-3):244-62.
37. Vargas BA, Bidone J, Oliveira LK, Koester LS, Bassani VL, Teixeira HF. Development of topical hydrogels containing genistein-loaded nanoemulsions. J Biomed Nanotechnol. 2012;8(2):330-6.
38. Si HY, Li DP, Wang TM, Zhang HL, Ren FY, Xu ZG, et al. Improving the anti-tumor effect of genistein with a biocompatible superparamagnetic drug delivery system. J Nanosci Nanotechnol. 2010;10(4):2325-31.
39. Zampieri ALTC, Ferreira FS, Resende ÉC, Gaeti MPN, Diniz DGA, Taveira SF, et al. Biodegradable polymeric nanocapsules based on poly(DL-lactide) for genistein topical delivery: obtention, characterization and skin permeation studies. J Biomed Nanotechnol. 2013;9(8):527-34.
40. Lewis BA, Engelman DM. Lipid bilayer thickness varies linearly with acyl chain-length in fluid phosphatidylcholine vesicles. J Mol Biol. 1983;166(2):211-7.
41. Lis LJ, Mcalister M, Fuller N, Rand RP, Parsegian VA. Interactions between neutral phospholipid-bilayer membranes. Biophys J. 1982;37(3):657-65.
42. Balgavy P, Dubnickova M, Kucerka N, Kiselev MA, Yaradaikin SP, Uhrikova D. Bilayer thickness and lipid interface area in unilamellar extruded 1,2-diacylphosphatidylcholine liposomes: a small-angle neutron scattering study. BBA Biomembr. 2001;1512(1):40-52.
43. Lemarchand C, Couvreur P, Vauthier C, Costantini D, Gref R. Study of emulsion stabilization by graft copolymers using the optical analyzer Turbiscan. Int J Pharm. 2003;254(1):77-82.
44. Celia C, Trapasso E, Cosco D, Paolino D, Fresta M. Turbiscan lab expert analysis of the stability of ethosomes and ultradeformable liposomes containing a bilayer fluidizing agent. Colloids Surf B: Biointerfaces. 2009;72(1):155-60.
45. Go ML, Ngiam TL. Thermodynamics of partitioning of the antimalarial drug mefloquine in phospholipid bilayers and bulk solvents. Chem Pharm Bull. 1997;45(12):2055-60.
46. Wenk MR, Fahr A, Reszka R, Seelig J. Paclitaxel partitioning into lipid bilayers. J Pharm Sci. 1996;85(2):228-31.
47. Fahr A, van Hoogevest P, May S, Bergstrand N, Leigh MLS. Transfer of lipophilic drugs between liposomal membranes and biological interfaces: consequences for drug delivery. Eur J Pharm Sci. 2005;26(3-4):251-65.
48. Fredenberg S, Wahlgren M, Reslow M, Axelsson A. The mechanisms of drug release in poly(lactic-co-glycolic acid)-based drug delivery systems-a review. Int J Pharm. 2011;415(1-2):34-52.
49. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285(21):1182-6.
50. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009;15(3):220-31.
51. Wang Z, Ho PC. A nanocapsular combinatorial sequential drug delivery system for antiangiogenesis and anticancer activities. Biomaterials. 2010;31(27):7115-23.
52. Hartveit F, Halleraker B. Effect of subcutaneous transplants of Ehrlich carcinoma on the survival time of mice with intraperitoneal transplants of the same tumour. J Pathol. 1971;105(2):85-93.
53. Pasquier E, Honore S, Pourroy B, Jordan MA, Lehmann M, Briand C, et al. Antiangiogenic concentrations of paclitaxel induce an increase in microtubule dynamics in endothelial cells but not in cancer cells. Cancer Res. 2005;65(6):2433-40.
54. Shchors K, Evan G. Tumor angiogenesis: cause or consequence of cancer? Cancer Res. 2007;67(15):7059-61.
55. Roskoski Jr R. Vascular endothelial growth factor (VEGF) signaling in tumor progression. Crit Rev Oncol Hematol. 2007;62(3):179-213.
56. Banerjee S, Li Y, Wang Z, Sarkar FH. Multi-targeted therapy of cancer by genistein. Cancer Lett. 2008;269(2):226-42.
57. Yoshiji H, Harris SR, Thorgeirsson UP. Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast carcinoma cells. Cancer Res. 1997;57(18):3924-8.